Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Completed 14Terminated 6Recruiting 4Active not recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 13INDUSTRY 6NETWORK 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

birtamimab 3melflufen 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT05839626 2026-05-27

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Sanofi

Phase 1 Terminated
32 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT02312206 2023-11-14

VITAL

Prothena Biosciences Ltd.

Phase 3 Terminated
260 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02603172 2019-09-23

A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

GlaxoSmithKline

Phase 1 Terminated
23 enrolled 25 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02613182 2019-05-16

OLE

Prothena Biosciences Ltd.

Phase 2 Terminated
34 enrolled 10 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03154047 2019-03-26

Study in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 2 Terminated
80 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡